KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature

被引：29

作者：

de Reynies, Aurelien ^{[1
]}

Biol, Valerie ^{[2
]}

Milano, Gerard ^{[3
]}

Faivre, Jean ^{[4
]}

Laurent-Puig, Pierre ^{[5
]}

机构：

[1] Ligue Natl Contre Canc, Paris, France

[2] Inst Gustave Roussy, Villejuif, France

[3] Inst Antoine Lacassagne, Nice, France

[4] Univ Bourgogne, Ctr Hosp Univ Dijon, F-21004 Dijon, France

[5] Univ Paris 05, AP HP, Inst Natl St Rech Med U775, Paris, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 13期

关键词：

D O I：

10.1200/JCO.2007.15.9186

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：228 / 2230

页数：4

共 4 条

[1] KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab [J].

De Roock, W. ;

Piessevaux, H. ;

De Schutter, J. ;

Janssens, M. ;

De Hertogh, G. ;

Personeni, N. ;

Biesmans, B. ;

Van Laethem, J. -L. ;

Peeters, M. ;

Humblet, Y. ;

Van Cutsem, E. ;

Tejpar, S. .

ANNALS OF ONCOLOGY, 2008, 19 (03) :508-515

[2] Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy [J].

Di Fiore, F. ;

Blanchard, F. ;

Charbonnier, F. ;

Le Pessot, F. ;

Lamy, A. ;

Galais, M. P. ;

Bastit, L. ;

Killian, A. ;

Sesboue, R. ;

Tuech, J. J. ;

Queuniet, A. M. ;

Paillot, B. ;

Sabourin, J. C. ;

Michot, F. ;

Michel, P. ;

Frebourg, T. .

BRITISH JOURNAL OF CANCER, 2007, 96 (08) :1166-1169

[3] Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab [J].

Khambata-Ford, Shirin ;

Garrett, Christopher R. ;

Meropol, Neal J. ;

Basik, Mark ;

Harbison, Christopher T. ;

Wu, Shujian ;

Wong, Tai W. ;

Huang, Xin ;

Takimoto, Chris H. ;

Godwin, Andrew K. ;

Tan, Benjamin R. ;

Krishnamurthi, Smitha S. ;

Burris, Howard A., III ;

Poplin, Elizabeth A. ;

Hidalgo, Manuel ;

Baselga, Jose ;

Clark, Edwin A. ;

Mauro, David J. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (22) :3230-3237

[4] KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer [J].

Lièvre, A ;

Bachet, JB ;

Le Corre, D ;

Boige, V ;

Landi, B ;

Emile, JF ;

Côté, JF ;

Tomasic, G ;

Penna, C ;

Ducreux, M ;

Rougier, P ;

Penault-Llorca, F ;

Laurent-Puig, P .

CANCER RESEARCH, 2006, 66 (08) :3992-3995

← 1 →